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Accepted 12 March 2020; Published online 17 March 2020AbstractObjectives: Electronic health records (EHR) provide a valuable resource for assessing drug side-effects, but treatments are not
randomly allocated in routine care creating the potential for bias. We conduct a case study using the Prior Event Rate Ratio (PERR) Pair-
wise method to reduce unmeasured confounding bias in side-effect estimates for two second-line therapies for type 2 diabetes, thiazolidi-
nediones, and sulfonylureas.
Study Design and Settings: Primary care data were extracted from the Clinical Practice Research Datalink (n 5 41,871). We utilized
outcomes from the period when patients took first-line metformin to adjust for unmeasured confounding. Estimates for known side-effects
and a negative control outcome were compared with the A Diabetes Outcome Progression Trial (ADOPT) trial (n 5 2,545).
Results: When on metformin, patients later prescribed thiazolidinediones had greater risks of edema, HR 95% CI 1.38 (1.13, 1.68) and
gastrointestinal side-effects (GI) 1.47 (1.28, 1.68), suggesting the presence of unmeasured confounding. Conventional Cox regression over-
estimated the risk of edema on thiazolidinediones and identified a false association with GI. The PERR Pairwise estimates were consistent
with ADOPT: 1.43 (1.10, 1.83) vs. 1.39 (1.04, 1.86), respectively, for edema, and 0.91 (0.79, 1.05) vs. 0.94 (0.80, 1.10) for GI.
Conclusion: The PERR Pairwise approach offers potential for enhancing postmarketing surveillance of side-effects from EHRs but
requires careful consideration of assumptions.  2020 The Authors. Published by Elsevier Inc. This is an open access article under
the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords: PERR Pairwise; Electronic health record; Unmeasured confounding; Side-effects; Observational data; Pharmacovigilance1. Introduction
Postmarketing surveillance of new drugs (pharmacovigi-
lance) is vital to ensure that patients receive safe and effec-
tive treatments. Longitudinal data from electronic health
record (EHR) systems, such as the Clinical Practice
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4.0/).increasingly important data source to study therapy effec-
tiveness and risk of side-effects. A major challenge in uti-
lizing observational data; however, is that patients are not
randomly allocated to treatment as in a randomized
controlled trial (RCT). For example, confounding by indi-
cation can arise where doctors preferentially prescribe
one medication over another based on indication, severity,
or prognosis [1e3]. A confounding variable (or
confounder) is a variable that is related to both the alloca-
tion of treatment and the outcome (e.g., high BMI is asso-
ciated with both statin prescribing and risk of
cardiovascular events [4]). In practice, allocation to treat-
ment may be subject to an unrecognized or unmeasured
process (unmeasured confounding). Comparisons of treat-
ment effects will be biased when one or more confounderss article under the CC BY license (http://creativecommons.org/licenses/by/
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Key findings
 Conventional analyses of side-effects based on
adjustment for available confounders in electronic
health record data gave results that were inconsis-
tent with randomized trial estimates for one known
side-effect of thiazolidinediones (edema) and one
negative control outcome (gastrointestinal).
 Compared with conventional estimates, application
of the Prior Event Rate Ratio (PERR) Pairwise
method yielded estimates of side-effect risk that
were more consistent with those observed in a
large randomized trial of the same therapies.
What this adds to what was known?
 This case study provides the first substantive appli-
cation of the PERR Pairwise method and shows
how it can reduce unmeasured confounding in
side-effect studies using EHR data; user-friendly
R code to apply the PERR Pairwise method is
provided.
What is the implication and what should change
now?
 Unmeasured confounding is a threat to the validity
of observational studies of drug side-effects.
 Researchers conducting pharmacovigilance studies
using EHR data should consider the application of
the PERR Pairwise approach to detect and adjust
for unmeasured confounding.
is unmeasured, and this bias cannot be removed using stan-
dard analytical approaches.
Overcoming unmeasured confounding is a key challenge
when drawing inferences from EHRs, and a growing num-
ber of approaches have been developed to address this. His-
torically, the principal approaches were instrumental
variable (IV) analysis [5e7] and difference-in-differences
[8]. Recent developments include the missing cause
approach [9], regression discontinuity designs [10] and pro-
pensity score calibration [11,12]. Each of these methods re-
lies on specific assumptions and can only be used for
selected data structures. Comprehensive reviews are found
in the study by Uddin et al., Streeter et al., and Alemayehu
et al [13e15]. This study demonstrates the application of
another promising approach to address unmeasured con-
founding in nonrandomized studies, the Prior Event Rate
Ratio (PERR) method [16e18]. PERR is designed to
reduce bias when comparing time-to-event or count out-
comes between treatments, after the initiation of a new
treatment. It is an extension of conventional regression-
L.R. Rodgers et al. / Journal of Clbased approaches that exploits a before-and-after design
to remove the effect of unmeasured confounders.
The conventional approach involves comparing outcome
event rates after treatment initiation in individuals pre-
scribed the treatment of interest (exposed group) compared
with individuals prescribed a comparator treatment (unex-
posed group). Adjustment for baseline measured con-
founders is typically made using Cox proportional
hazards (PH) regression. Differences between groups are
summarized as a hazard ratio (HRs, where s denotes the
study period, i.e., follow-up from the initiation of treat-
ment). In EHR databases, information may also be avail-
able on the outcomes of interest before the initiation of
the treatment (i.e., before the study baseline). A simple
approach to accounting for group differences in prior out-
comes [19] could add a binary indicator for a previous
event in a study period model; however, this would not ac-
count for unobservable characteristics. PERR methodology
extends this approach by incorporating differences in event
rates between exposed and unexposed groups in the period
before treatment initiation in the statistical model. The dif-
ference in event rates is represented as HRp. Because
neither group receives the treatment of interest during the
prior period, HRp, with certain assumptions, reflects the in-
fluence of unmeasured confounders independent of treat-
ment. The PERR adjusted hazard ratio, HRPERR, is
calculated as HRs/HRp, and provides an estimate of the
treatment effect adjusted for both measured and unmea-
sured confounders. The method requires the effect of the
confounders (measured and unmeasured) to remain the
same between periods (time-invariant unmeasured con-
founding) and treatment allocation for the study period
not to be influenced by the outcome in the prior period
(treatment decision to be independent of prior events)
[17,18,20,21]. It is important to note that PERR is only
applicable for nonterminal events which can reoccur in
both periods; Appendix A has further details of PERR
and relevant assumptions for its use.
Simulation studies [4,12,17] have explored the perfor-
mance of the PERR method in a range of scenarios and
demonstrated that it can produce biased treatment effect es-
timates when there is a relationship between prior outcomes
and treatment selection or changes in the confounder effect
between periods (time-varying unmeasured confounding).
The original PERR approach is based on fitting two models
which separate patient response in each period; recent work
has developed an alternative formulation that keeps these
data paired, using within-person comparisons to address
the effects of time-invariant confounding. The PERR
method was also shown in some cases to produce attenu-
ated treatment effect estimates [17,18]; this bias is a conse-
quence of the nonlinearity of the Cox model. PERR-ALT
[17] is an alternative formulation using paired Cox regres-
sion which overcomes these issues. In PERR-ALT, HRE is
the HR comparing event rates in the study vs. prior period
in the exposed group, and HRU is the same comparison in
80 L.R. Rodgers et al. / Journal of Clinical Epidemiology 122 (2020) 78e86the unexposed. HRPERR-ALT is calculated as HRE/HRU. An
extension to this methodology, PERR Pairwise [18], is
based on the pairwise likelihood formulation of PERR-
ALT.
Here, we set out to provide the first practical application
of the PERR Pairwise method. As a case study, we aimed to
apply PERR methodology to estimate risk of known side-
effects from EHR data for medications commonly pre-
scribed to lower blood glucose in type 2 diabetes (T2D),
sulfonylureas (SUs), and thiazolidinediones (TZDs), and
to compare the results with estimates from trial data in
which participants were randomized to treatment.2. Methods
2.1. Prior event rate ratio
Conventional analyses utilize data on confounders
measured at the baseline and may include adjustment for
prior events. PERR methodology adds an extra stage by se-
lection of patients who have data available before initiation
of new treatment and modeling of outcomes during thisFig. 1. How to compute the PERR, PERR-ALT, and Pairwise eprior period (Appendix B). The time between starting the
prior observation period and starting the study period is a
parameter which should be chosen with care; a ratio
method requires that the influence of the unmeasured con-
founders remain the same in the prior and study periods.
The gap needs to be short enough to maintain the assump-
tion of time-invariant confounding while long enough to
ensure sufficient numbers of prior events are captured
[17,18,21].
There are three formulations of PERR [16e18], summa-
rized in Fig. 1 and Appendix A. We provide a worked
example to enable other researchers to replicate this method
easily. R code illustrating the computations for each
method is provided (Supplementary 2). PERR-ALT and
the newer Pairwise method reduce the bias inherent in the
original PERR approach [17,18] and can be considered
equivalent as both use paired Cox regression. The standard
errors (SE) from PERR-ALT/Pairwise will often be larger
than that of PERR [18] as patients only contribute if they
have an event; for rare events, these formulations are less
computationally stable than PERR. A computational limita-
tion of PERR and PERR-ALT is that bootstrapping isstimates. Abbreviations: PERR, Prior Event Rate Ratio.
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likelihood and produces direct estimates of SE. Given the
computational advantages of using PERR Pairwise when
faced with large sample sizes in EHR databases, we report
Pairwise estimates as our selected within-subject approach
with a note that PERR-ALT is an alternative. The PERR
Pairwise approach also provides a natural framework for
extending the method to address additional sources of
complexity. For example, the underlying Pairwise model
has a flexible period effect term which allows the propor-
tional baseline hazards assumption to be relaxed in cases
where the assumption is not met ([18]; Appendix A).
Our approach is first to investigate the influence of con-
founding using separate adjusted Cox PH models fitted to
each period. Estimates of group differences in the prior
period reflect differences in populations before the treat-
ment was started and provide a measure of the degree of
unmeasured confounding. An HR 95% confidence interval
(CI) which does not contain 1 indicates a potential differ-
ence between the groups before allocation to the new treat-
ment. However, even if 1 is contained within this interval,
we recommend that the PERR method should still be
applied [17]; only if PERR estimates are comparable with
the study period Cox models that we can conclude no evi-
dence of unmeasured confounding.2.2. Case study: side-effects on type 2 diabetes
medication
Patients with T2D are prescribed metformin (MFN) as
first-line therapy; we use the experience of time on MFN
as the period before the start of treatment [22]. Two com-
mon second-line treatments are TZD and SU. Known
side-effects to TZDs are peripheral edema [23] and weightFig. 2. Schematic of Prior Event Rate Ratio method for our case study
the ‘‘exposed’’ group in the standard definitions of the PERR methodolog
Pre-exposure and follow-up periods are up to 2 y. Abbreviations: SU, sulfo
Rate Ratio.gain [24]; obtaining valid estimates of the rates of these in
EHRs requires consideration of sources of confounding. We
apply PERR Pairwise to assess and reduce the effect of any
unmeasured confounding. In applications of PERR, we
define an exposed and unexposed group; here, the TZD
group is the exposed equivalent and SU the unexposed
(Fig. 2). Gastrointestinal side-effects (GI) are not known
to be associated with TZDs and are used as a negative con-
trol outcome (NCO) to test the robustness of the method.
STROBE [25] guidelines were used to ensure transparency
in our approach (Supplementary 1).
Patients with T2D were extracted on August 8, 2016
from CPRD [26]. The average year starting MFN was
2004 (Table 1). Patients who were prescribed MFN as their
first-line treatment followed by SU or TZD were selected
for the study; Fig. 2. The closest run of MFN treatment
to the SU/TZD was used, followed by the first instance of
SU/TZD. Two-year follow-up was used in each of the pe-
riods with the time recorded until patients experienced a
side-effect, stopped/added to current treatment, died, or left
the practice. 41,871 patients met our study criteria (32,242
on SU, 9,629 on TZDs; Appendix C).
An important consideration for setting up the study is
the definition of periods; unmeasured factors influencing
an individual’s propensity for a side-effect independent of
treatment should stay the same in both periods. To ensure
this was a reasonable assumption, we restricted time be-
tween MFN and starting TZD/SU to 5 years; clinically,
we would expect to review a patient’s treatment regime
within this period. We tested the sensitivity of our analysis
to this period by restricting this to 3, 4, and 5 years [17],
with little difference in results (Appendix D).
Side-effect outcomes were edema, GI, and weight gain.
Medical codes for edema or GI identified the side-effects.. SU group are equivalent to the ‘‘Unexposed’’ group and TZD to
y. Time between start MFN and start SU/TZD is a maximum of 5 y.
nylurea; TZD, thiazolidinedione; MFN, metformin; PERR, Prior Event
Table 1. Descriptive statistics
Group Gender (female) Weight (kg) BMI Hba1c (mmol/mol [%])
SU Group (N 5 32,242)
Diagnosis 41% 95.0 (19.9) 15,404 33.1 (6.3)
15,384
75.8 (25.2) [9.1 (2.3)]
12,543
MFN period 93.3 (19.7) 25,681 32.5 (6.2)
25,637
77.7 (21.1) [9.3 (1.9)]
23,034
SU period 91.8 (19.7) 29,009 32.1 (6.1)
28,951
74.1 (17.6) [8.9 (1.6)]
28,423
TZD group (N 5 9,629)




78.3 (24.2) [9.3 (2.2)]
3,645














SU (N 5 1,258) 41.4 32.2 (6.3) 56.9 (10.1) [7.4 (0.9)]
TZD (N 5 1,287) 44.5 32.2 (6.4) 57.0 (10.1) [7.4 (0.9)]
Abbreviations: MFN, metformin; SU, sulfonylurea; TZD, thiazolidinedione; ADOPT, A Diabetes Outcome Progression Trial.
Mean (SD), median (IQR), or %. N reported where there are missing data.
82 L.R. Rodgers et al. / Journal of Clinical Epidemiology 122 (2020) 78e86Weight gain was calculated as change from the baseline
[26]. ChangesO20 kg were considered data errors and
excluded. Significant weight gain was an increase from
the baseline of 6% (5 kg increase in average baseline
weight). Two consecutive weights were required to ensure
that the weight gain was not temporary; the first falling
within the 2 years from treatment start and the second be-
tween the first and up to 2 years after the end of the period.
Cox PH models, adjusted for measured covariates, were
fitted to both periods. Unadjusted results are in Appendix
E, and details of adjusted models in Appendix F. Covariates
considered were baseline HbA1c, weight, BMI, age, dura-
tion of diabetes, gender, calendar year at the start of treat-
ment, and adherence to medication [27]. Variables
significant at the 10% level or withO15% influence on other
coefficients were retained in multivariate models. All cova-
riates were measured at the start of each period [26]. Where
the use of covariates changed the sample size, we refit unad-
justed models to the reduced sample to check whether results
remained the same and to help diagnose any bias due to
missing data. SQLyog and R version 3.3.1 were used.2.3. Comparisons with other data/methods
To evaluate the validity of PERR results, we made com-
parisons with findings of the A Diabetes Outcome Progres-
sion Trial (ADOPT) study [28]. ADOPT was a multicentre,
double-blind RCT evaluating the durability of glycemic
control on TZD (rosiglitazone, N 5 1,287), MFN, and
SU (glibenclamide, N 5 1,258). Patients were newly diag-
nosed (within 3 years) with T2D and had not beenpreviously prescribed T2D medication. ADOPT was suit-
able for comparison as it compares the drugs of interest
over a long period (4 years), the primary outcome was time
to treatment failure and treatments were monitored for
safety and tolerability. Side effects were well recorded.
We also compare PERR with an alternative method of
adjusting for events in the prior period: a Cox PH model
fitted to the data in the study period alone with an addi-
tional binary adjustment for whether the side-effect was
experienced in the prior period (Prior Adjusted Study
Model, PASM).3. Results
Some differences in characteristics between patients who
went on to TZDs as a second-line therapy compared with
those who went on to SU were seen (Table 1); patients
who were heavier and diagnosed younger tended to be pre-
scribed TZDs rather than SU as second-line therapy (mean
(SD): 93 (20) kg SU, 98 (21) kg TZD and 58 (11) yrs SU
56 (10) yrs TZD.) Minor differences in HbA1c and BMI
were also seen at diagnosis. These may imply some pre-
scriber bias. Both groups moved on to second-line therapy
on similar time scales. ADOPT study patients were newly
diagnosed and have a shorter duration of diabetes than the
EHR patients; BMI and HbA1c at diagnosis are also lower.
3.1. Example 1: edema
The rate of edema on MFN was higher in the TZD
group, 1.8% (n 5 177), than the SU group, 1.3%
Age (y) Duration of diabetes (y) Adherence % Calendar year of start Time from MFN start (mo)
58.2 (11.0)
59.9 (11.2) 1.7 (2.2) 87.9 (22.3)
25,917
2,005.2 (5.0)
61.7 (11.3) 3.5 (2.5) 89.7 (24.3)
23,039
2,007.1 (5.0) 19 [9e60]
56.2 (10.3)
57.6 (10.4) 1.4 (1.9) 90.1 (20.3)
8,248
2,004.1 (2.8)
59.4 (10.5) 3.2 (2.4) 92.5 (21.1)
8,205
2,005.9 (2.6) 18 [8e60]
SU 55.7 (10.1)
TZD 55.5 (9.9)
56.5 (10.2) 0.8 (0.9)
56.3 (10.0) 0.8 (0.9)
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observed in the study period, with risks of 5.2%
(n 5 498) vs. 2.4% (n 5 767) for TZD and SU groups,
respectively. The incidence of edema was higher in the
TZD group than the SU group in the prior period after
adjustment for measured confounders, HR 95% CI 1.39
(1.17, 1.66), Fig. 3. This difference suggests unmeasured
confounding; the group that later was prescribed TZDs
were more prone to edema. The study model indicates
the risk of edema is more than doubled in the TZD group,
2.07 (1.81, 2.37) with a similar estimate in the PASM, 2.03
(1.78, 2.32). ADOPT showed a greater risk of edema on
TZD but a smaller effect; 1.39 (1.04, 1.86). The PERR Pair-
wise analysis also showed a greater risk of edema with
TZDs but results more closely replicated ADOPT, 1.43
(1.10, 1.83), than PASM and the conventional Cox PH
model. The standard PERR analysis gave similar results
to PERR Pairwise.3.2. Example 2: weight gain
Patients had similar weight gain on MFN in both groups
(TZD: 5.8%, n 5 1,126; SU: 6.2%, n 5 356), but greater
gain when on TZD (23.8%, n 5 1.477) than SU (13.2%,
n 5 2.581). Comparison of adjusted models indicated little
influence of unmeasured confounding from group differ-
ences in the prior (Fig. 3): Cox study model, 1.70 (1.56,
1.84), and Pairwise, 1.52 (1.23, 1.88). The PASM and
PERR showed similar results, 1.69 (1.56, 1.84) and 1.58
(1.33, 1.90). EHR analyses found a greater risk of weight
gain for patients taking TZD relative to SU; the CIs over-
lapped the ADOPT trial, 1.36 (1.17, 1.58).3.3. Example 3: gastrointestinal side-effects
Patients in the TZDgroup experiencedmoreGI in both pe-
riods, 9.8% (n5 945) and 10.2% (n5 980), than those in the
SU group, 6.0% (n 5 1,948) and 6.4% (n 5 2,053). In
adjusted analyses, the CI in the prior period (1.28, 1.68;
Fig. 3), suggested unmeasured confounding. However, after
adjustment for unmeasured confounding using PERR Pair-
wise, there was no association between GI and TZD, 0.94
(0.80, 1.10), consistent with ADOPT, 0.91 (0.79, 1.05).
PERR produced a similar estimate, 1.09 (0.93, 1.29). The
PASM reduced the HR closer to that of ADOPT than the
study model alone, 1.52 (1.35, 1.71) vs. 1.60 (1.42, 1.80)
but did not remove the false association betweenGI andTZD.4. Discussion
We showed unmeasured confounding affected the anal-
ysis of side-effects of T2D medications using EHR data.
When adjustment for confounding using PERR Pairwise
was applied to edema, it yielded estimates consistent with
RCT data. In the NCO example, Pairwise eliminated the
false association between TZD and GI. Comparing the
PASM to the study model, the PASM did reduce the HRs.
However, PERR Pairwise gave estimates that were much
closer to the trial results than PASM. PASMdid not eliminate
the false association between TZD and GI. For weight gain,
there was no evidence of unmeasured confounding; and,
while the HR from the study period alone did overlap the
trial, the Pairwise estimate was closer to the ADOPT result.
This case study illustrates how PERR methodology is a
potentially useful approach to addressing unmeasured con-
founding in evaluation studies based on real-world data.
Fig. 3. Case study results: adjusted models, PERR Pairwise N 5 32,242 SU N 5 9,629 TZD in edema and gastrointestinal analyses, N 5 10,807
SU N 5 4,468 weight gain analysis. Column 4 shows percentage of patients who experience the side-effect in each period. An HR greater than 1
indicates a greater risk of side-effect in the TZD group relative to SU. An HR less than 1 indicates greater risk of a side-effect in the SU group. HR
from the prior and study are used to calculate PERR; PERR Pairwise is calculated by minimizing the negative log-likelihood of the paired Cox
model. Abbreviations: SU, sulfonylurea; TZD, thiazolidinedione; MFN, metformin; HR, hazard ratio; PERR, Prior Event Rate Ratio.
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PERR rather than PERR Pairwise. The original PERR
formulation estimates were closer to the clinical trial results
than the study model alone. However, the PERR estimates
were consistently further from the trial results than the Pair-
wise method and it is known that PERR does not
completely remove bias resulting from the nonlinearity of
the Cox model [18]. Pairwise produces larger SE ([18];
Appendix A) but this is unlikely to be a substantial
problem with EHR sample sizes. We advocate use of PERR
Pairwise as an additional component of the tool kit for
applied researchers tackling the issue of unmeasured con-
founding; only if this concurs with the adjusted Cox study
model can we conclude no evidence of unmeasured
confounding.
As with all adjustment methods for unmeasured con-
founding, the PERR approach requires certain assumptionsto be met to provide valid estimates. PERR-ALT/Pairwise
can produce unbiased estimates when the unmeasured con-
founding is time-invariant, but simulations showed that
time-dependent confounding is a potentially important
source of bias when applying the PERR approach
[4,17,18]; it cannot be removed from the data using avail-
able methods. The results of any study utilizing PERR,
including this one, are only valid under this assumption.
We addressed this issue by careful consideration of the time
between the start of the prior and start of the study period
with sensitivity analysis using shorter periods. Where
possible, the choice of a prior period should minimize the
risk of time-dependent confounding (e.g., limiting the time
between periods).
Sample size may also be an issue when adjusting for
baseline covariates, some of which are poorly recorded.
A limitation of EHR data is that reporting of outcomes
85L.R. Rodgers et al. / Journal of Clinical Epidemiology 122 (2020) 78e86may be incomplete and subject to error. Weight, in partic-
ular, was not well reported, and there is evidence of a
relationship between weight recorded and weight change
[29,30]; moreover, interval-censored data and imprecise
measuring times within our weight data could bias results
toward the null [31]. Both periods should be affected
similarly, but further work may be required to investigate
a complex picture of weight gain. Another assumption is
that prior events do not influence the likelihood of future
treatment. Previous work [4,18,20,21] showed bias in
PERR when prior events influence treatment selection.
Although this can be an issue in effectiveness studies, it
is less likely to be problematic when modeling side-
effects, under the assumption that treatments are not allo-
cated according to the potential (and possibly unknown)
side-effects of the treatment. However, further work is
required to assess the validity of this assumption before
PERR is recommended for widespread use in pharmacovi-
gilance studies.
Alternative approaches to unmeasured confounding
include IV analysis [5e7], regression discontinuity designs
[10], missing cause [9] and propensity score regression
calibration [12]. To date, there have been no studies which
have compared the relative merits of these methods with
PERR. There is no single solution to the problem of unmea-
sured confounding; exploring which methods perform best
under different conditions via clinically informed simula-
tions and case studies is necessary. The choice of method
will always depend on the particular case at hand; for
example, PERR inappropriate for terminal outcomes, IV
studies require a suitable instrument. With increasing vol-
ume of EHR data, there is a need to continue developing
these methods and to utilize these data as efficiently as
possible. One particular challenge and important topic for
future research is the need to identify strategies for address-
ing time-dependent unmeasured confounding.5. Conclusions
This article illustrates how to apply the PERR Pairwise
method in detecting and adjusting for unmeasured con-
founding when assessing risk of side-effects from EHR
data. It is relatively straightforward to implement and can
be used to provide ‘‘real-world’’ estimates of risk for both
known and emerging side-effects in pharmacovigilance
studies where trials are not available. The approach requires
strong assumptions and further work is needed to provide
guidance on addressing time-dependent confounding.CRediT authorship contribution statement
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